Corbus Historical Income Statement
| CRBP Stock | USD 8.51 0.97 10.23% |
Historical analysis of Corbus Pharmaceuticals income statement accounts such as Interest Expense of 3.5 M, Selling General Administrative of 13.9 M or Other Operating Expenses of 50.8 M can show how well Corbus Pharmaceuticals Holding performed in making a profits. Evaluating Corbus Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Corbus Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Corbus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Corbus Pharmaceuticals is a good buy for the upcoming year.
Corbus |
About Corbus Income Statement Analysis
Corbus Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Corbus Pharmaceuticals shareholders. The income statement also shows Corbus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Corbus Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Corbus Pharmaceuticals. It is also known as Corbus Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Corbus Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Corbus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. At this time, Corbus Pharmaceuticals' Interest Expense is relatively stable compared to the past year. As of 02/16/2025, Research Development is likely to grow to about 36.9 M, while Other Operating Expenses is likely to drop slightly above 50.8 M.
Corbus Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Corbus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Corbus Pharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 1.7M | 1.6M | 1.5M | 641K | 737.2K | 651.3K | |
| Interest Expense | 1.0M | 1.8M | 2.1M | 2.9M | 3.4M | 3.5M | |
| Selling General Administrative | 28.5M | 20.4M | 18.7M | 13.9M | 16.0M | 13.9M | |
| Other Operating Expenses | 126.7M | 56.9M | 34.8M | 45.1M | 51.8M | 50.8M | |
| Operating Income | (122.8M) | (56.0M) | (39.8M) | (45.1M) | (40.6M) | (42.6M) | |
| Ebit | (123.4M) | (56.6M) | (40.2M) | (45.1M) | (40.6M) | (42.6M) | |
| Research Development | 98.3M | 36.4M | 16.1M | 31.2M | 35.8M | 36.9M | |
| Ebitda | (121.7M) | (55.0M) | (38.7M) | (44.4M) | (40.0M) | (42.0M) | |
| Total Operating Expenses | 126.7M | 56.9M | 34.8M | 13.9M | 16.0M | 15.2M | |
| Income Before Tax | (111.3M) | (45.6M) | (42.3M) | (44.6M) | (40.1M) | (42.2M) | |
| Total Other Income Expense Net | 11.5M | 10.3M | (2.5M) | 474.0K | 545.1K | 517.8K | |
| Net Income | (111.3M) | (45.6M) | (55.8M) | (44.6M) | (40.1M) | (42.2M) | |
| Income Tax Expense | (2.3M) | 35.0K | (87.8K) | 13.5M | 15.5M | 16.3M | |
| Gross Profit | 3.8M | (757.5K) | (1.5M) | (31.2M) | (28.1M) | (26.6M) | |
| Net Income From Continuing Ops | (111.3M) | (45.6M) | (42.3M) | (47.5M) | (42.7M) | (44.9M) | |
| Cost Of Revenue | 98.3K | 1.6M | 1.5M | 31.2M | 35.8M | 37.6M | |
| Net Income Applicable To Common Shares | (71.5M) | (111.3M) | (45.6M) | (42.3M) | (38.1M) | (40.0M) | |
| Net Interest Income | (1.0M) | (1.8M) | (2.1M) | (2.9M) | (2.6M) | (2.4M) | |
| Reconciled Depreciation | 1.7M | 1.6M | 1.5M | 1.4M | 1.6M | 1.3M |
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.